Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPa macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. It is conducting a Phase IA/B clinical trial in patients with acute myeloid leukemia (AML) and HR-MDS. It has completed the Phase IA dose-escalation portion of this clinical trial and are enrolling patients in the Phase IB expansion cohorts evaluating SL-172154 in combination with azacitidine in frontline HR-MDS or frontline TP53 mutant (TP53m) AML. It has developed the ARC platform to address the need for a single therapeutic that consolidates multiple immune functions.
企業コードSTTK
会社名Shattuck Labs Inc
上場日Oct 09, 2020
最高経営責任者「CEO」Dr. Taylor Schreiber, M.D., Ph.D.
従業員数44
証券種類Ordinary Share
決算期末Oct 09
本社所在地500 W. 5Th Street
都市AUSTIN
証券取引所NASDAQ Global Select Consolidated
国United States of America
郵便番号78701
電話番号15129004690
ウェブサイトhttps://www.shattucklabs.com/
企業コードSTTK
上場日Oct 09, 2020
最高経営責任者「CEO」Dr. Taylor Schreiber, M.D., Ph.D.
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし